Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Running, not enrolling · Phase 1 · Has a placebo group

Conditions studied: Overweight, Obesity

In brief

The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.

Key facts

Study ID

NCT07229157

Run by

Amgen

People needed

81

Starts

2025-10-22

Expected to finish

2026-08-26

Last updated by the study team

2026-01-23

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To take part in the trial, participants must meet all of the following:
• Provide signed and dated informed consent before any trial procedures.
• Be able to understand the trial requirements, sign the consent form, and follow trial restrictions.
• Male or female, of any race, between 18 and 60 years old (inclusive).
• Females must not be pregnant or breastfeeding.
• Males and females who could become pregnant must agree to use effective birth control as specified in the protocol.
• Body mass index (BMI) between 25.0 and 35.0 kg/m\^2 (inclusive).
• No major changes in diet or lifestyle in the past 3 months, based on self-report.
• Stable body weight (less than 5 kg change) in the past 3 months, based on self-report.
• Blood potassium, calcium, and magnesium within the normal range at screening and at check-in for the first treatment period.
• Participants with controlled high blood pressure, cholesterol problems, or hypothyroidism on stable treatment for at least 3 months may be included (except for medicines known to affect heart rhythm or interact with moxifloxacin). Other mild, stable health conditions may be allowed with approval from the investigator and medical monitor.

You may not qualify if…

• Participants will not be able to take part if they meet any of the following:
• Medical Conditions
• Any significant medical condition or abnormal test result that, in the opinion of the investigator, could pose a risk or interfere with trial participation.
• History of diabetes (any type, except past gestational diabetes), or Haemoglobin A1c (HbA1c) ≥ 6.5% at screening.
• History of pancreatitis within the past year, or high blood tests suggesting pancreatic problems (lipase/amylase > 2× normal, or fasting triglycerides > 500 mg/dL).
• Liver enzymes (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) more than 2× the upper limit of normal.
• Kidney function (estimated glomerular filtration rate [eGFR]) < 70 mL/min/1.73 m\^2.
• Cancer within the last 5 years (except treated nonmelanoma skin cancers or in situ cervical/breast lesions).
• Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
• Uncontrolled thyroid disease (abnormal thyroid-stimulating hormone [TSH] outside 0.4-6.0 mIU/L).
• Contraindications to moxifloxacin, including history of tendon disorders with quinolone use.
• History of gastrointestinal surgery or disease that may affect absorption of oral drugs (other than uncomplicated appendectomy or hernia repair).
• Inability to swallow pills.
• History of significant esophageal, stomach, or bowel disorders (eg, ulcers, bleeding, Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastroparesis).
• Current or recent suicidal thoughts (per Columbia Suicide Severity Rating Scale [C-SSRS]).
• Lifetime history of suicide attempt or behavior.
• Major depressive disorder within the past 2 years.
• History of other serious psychiatric disorders (eg, schizophrenia, bipolar disorder).
• High depression score (patient health questionnaire-9 [PHQ-9] ≥ 15).
• History or current signs of heart disease (eg, heart attack, congenital defects, valve disease, angina, bypass or stent).
• History of ischemic optic neuropathy (eye damage from poor blood flow).
• Diagnosis of sleep apnea. Diagnostic Tests
• Positive test for human immunodeficiency virus (HIV).
• Positive test for hepatitis B or C (exceptions apply for prior vaccination or resolved infection).
• Abnormal vital signs: average blood pressure > 140/90 mmHg or < 90/50 mmHg, or heart rate > 110 or < 40 bpm.

Where it is running

• Fortrea Clinical Research Unit - Daytona Beach — Daytona Beach, Florida, United States
• Fortrea Clinical Research Unit - Dallas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.